Vulvar Pain Syndromes a Bounty of Treatments— but Not All of Them Are Proven

Total Page:16

File Type:pdf, Size:1020Kb

Vulvar Pain Syndromes a Bounty of Treatments— but Not All of Them Are Proven second of 3 parTs VulVar paIn syndroMes a bounty of treatments— but not all of them are proven Treatments for vulvodynia and vestibulodynia range from lifestyle adjustments and application of topical agents to tricyclic antidepressants and nerve blocks— but the data on their efficacy are not as bountiful neal M. lonky, Md, MpH, moderator; libby edwards, Md, Jennifer Gunter, Md, and Hope K. Haefner, Md, panelists s we discussed in the first installment vulva. Cool gel packs are sometimes helpful. of this three-part series in the Sep- In thIs When it comes to intercourse, I recom- Article A tember issue of OBG Management, mend adequate lubrication using any of a the causes of vulvar pain are many, and the number of effective products, such as olive Therapies discussed diagnosis of this common complaint can be oil, vitamin E oil, Replens, Slippery Stuff, As- by the panel difficult. Once the diagnosis of vulvodynia troglide, KY Liquid, and others. page 34 has been made, however, the challenge shifts There is an extensive list of lubricants at to finding an effective treatment. Here, our http://www.med.umich.edu/sexualhealth/ How to determine expert panel discusses the many options resources/guide.htm which treatments available, the data (or lack of it) behind each are best therapy, and what to do in refractory cases. In Part 3 of this series, in the November Topical agents might offer relief page 35 issue, the focus will be vestibulodynia. —but so might placebo Dr. Lonky: What is the role of topical medi- Is physical therapy cations, including anesthetics, for treating underrated? Management of vulvar pain vulvar pain syndromes? page 38 begins with simple measures Dr. Edwards: I don’t find topical medica- Dr. Lonky: How do you approach treatment tions to be particularly useful in the treat- of vulvar pain syndromes? ment of vulvodynia, except for lidocaine 2% Dr. Haefner: I often advise the patient to jelly, or lidocaine 5% ointment, which tends begin with simple measures. For example, I to burn with application—but I never start a recommend that she wear cotton underwear patient on only one medication, so judging during the day, but no underwear at night. If the effectiveness of a topical therapy is diffi- she perspires with exercise, wicking under- cult in that context. Good studies of topical wear may be helpful. I also counsel the pa- medications in the treatment of vulvar pain tient to avoid vulvar irritants, douches, and syndromes are lacking, other than the recent the application of soap of any kind to the report on amitriptyline and baclofen.1 continued on pAge 30 obgmanagement.com Vol. 23 No. 10 | October 2011 | OBG Management 29 Vulvar pain syndromes hypoestrogenic changes in postmenopausal The OBG ManaGeMent expert panel women. Some providers use a high-dose, compounded topical estrogen with lido- Neal M. lonky, Md, MpH, moderator of this discussion, caine for vestibulodynia. Certainly, local hy- is Clinical Professor of Obstetrics and Gynecology at the poestrogenic changes should be reversed in University of California–Irvine and a member of the Board of Directors of Southern California Permanente Medical Group. postmenopausal women before a diagnosis He serves as an OBG ManageMent Contributing Editor. of vulvodynia or vestibulodynia is given. As for other topical therapies, they are widely used. Some women report improve- ment with application of plain petrolatum.2 Libby edwards, Md, is Adjunct Clinical Associate Professor Response rates of 33% to 46% after use of a of Dermatology at the University of North Carolina in Chapel topical placebo for vestibulodynia are well Hill, NC, and Chief of Dermatology at Carolinas Medical described in the literature.3,4 Center in Charlotte, NC. Dr. Edwards is a Past President and Past Secretary General of the International Society for the Topical analgesics are used frequently, Study of Vulvovaginal Disease. either sporadically (during pain flares) or regularly (daily application). One method of application for localized vestibulodynia Jennifer Gunter, Md, is Director of Pelvic Pain and involves liberally coating a cotton ball with Vulvovaginal Disorders for Kaiser Permanente in San lidocaine 5% and then applying it to the ves- Francisco, Calif. tibule overnight (for at least 8 hours of ex- posure). In this study, after 7 weeks, 76% of women were able to be sexually active, com- pared with 36% before the start of treatment. However, a randomized, placebo-controlled Hope K. Haefner, Md, is Professor of Obstetrics and trial that included lidocaine 5% cream in one Gynecology at the University of Michigan Hospitals and arm identified only a 20% reduction in pain Co-Director of the University of Michigan Center for Vulvar for women who had localized vestibulodyn- Diseases in Ann Arbor, Mich. ia—although, in this trial, the lidocaine was massaged into the vestibule four times daily.5 In this study, interestingly enough, topical lidocaine was less effective than topical pla- 3 The authors report no financial relationships relevant to this article. cebo, which produced a 33% response rate. Lidocaine gel has also been used, al- though some women report more local irri- Dr. Haefner: For minor degrees of pain, con- tation with gel than with ointment. sider lidocaine 5% ointment. Dr. Lonky: Do we have any data on topical lidocaine/prilocaine (eutectic mixture of application of other drugs? local anesthesia or LMX) may be used but Dr. Gunter: Compounded adjuvant medica- can be irritating. tions have been evaluated. In a retrospective doxepin 5% cream can be applied to skin study of topical gabapentin in a Lipoderm daily, gradually increasing the number of base, women who had generalized or local- daily applications to as many as four. ized vulvodynia applied a dose of 2%, 4%, or Topical amitriptyline 2% with baclofen 6% three times daily. Of these women, 80% 2% in a water washable base has also been experienced a reduction of at least 50% in the used for point tenderness (squirt 0.5 cc from pain score. In addition, 67% of patients who a syringe onto the finger and apply it to the had localized vestibular pain were able to re- affected area three times a day).1 sume intercourse.6 Dr. Gunter: Topical estrogen is prescribed A retrospective review of 38 women who by many providers, but we lack studies sup- used 2% amitriptyline and 2% baclofen in porting its efficacy, except for reversing a lipoderm cream for localized vestibular 30 OBG Management | October 2011 | Vol. 23 No. 10 obgmanagement.com Vulvar pain syndromes pain found that 53% experienced an im- varies, depending on the age of the patient provement in symptoms of at least 60%, but and the particular agent used. Amitripty- there was no change in the frequency of sex- line is often used as a first-line medication. ual intercourse.1 I start the patient on 10 to 25 mg nightly and increase that amount by 10 to 25 mg weekly, not to exceed 150 mg daily. A sample regi- do tricyclic antidepressants men might be 10 mg at bedtime for 1 week. ease chronic pain? If symptoms persist, increase the dose to Dr. Lonky: Let’s talk, for a moment, about 20 mg at bedtime for another week, and so the use of oral tricyclic antidepressants in the on. Once a dose is established that provides treatment of vulvar pain syndromes. What relief, the patient should continue to take do we know? that amount nightly. Advise the patient not Dr. Haefner: Tricyclic antidepressants are to discontinue the drug abruptly. Rather, it a common treatment for vulvar pain. This should be weaned. group of drugs (including amitriptyline In patients who are 60 years or older, [Elavil], nortriptyline [Pamelor], and desip- I give a starting dose of 5 to 10 mg and in- ramine [Norpramin]) has been used to treat crease it by 10 mg weekly. many idiopathic chronic pain conditions. In all age groups, it is important to ad- Published and presented reports indicate vise patients to avoid consuming more than that these drugs elicit about a 60% response one alcoholic beverage daily while taking rate for various pain conditions. A trial by the this medication. And in reproductive-age National Institutes of Health (NIH) is under women, contraception is critical. way, analyzing the use of antidepressants in Dr. Edwards: I call these drugs tricyclic “Because of their women who have vulvar pain. medications rather than antidepressants. low cost and their Although treatment with tricyclic anti- They are extremely useful in managing the effective ness, depressants has generally been reserved for neuropathic component of vulvar pain. De- tricyclic medications women who have generalized vulvodynia, spite a recent, apparently well-conducted are my first-line recent reports have found these medications study showing a lack of benefit, my 25 years therapy” to be helpful in the treatment of vestibu- of personal clinical experience with tricyclics —libby edwards, Md lar pain as well. The mechanism of action convince me that I should wait for follow-up is thought to be related to inhibition of the studies before abandoning this therapy.3 reuptake of transmitters—specifically, nor- The pain literature reports that higher epinephrine and serotonin. However, the doses than previously reported of tricyclic mechanism of action may be more closely medications are needed for optimal man- related to anticholinergic effects. Tricyclics agement of neuropathic pain. Doses from affect sodium channels and the N-methyl-d- 100 to 150 mg are often required for substan- aspartate (NMDA) receptor. tial improvement, and a major design flaw in If you choose to prescribe one of these many studies of the effect of tricyclic medi- medications, consider emphasizing to the cations on vulvodynia is the use of an insuf- patient its effect on the sensation of pain ficient dose.
Recommended publications
  • NVA Research Update E- Newsletter September – October – November 2016
    NVA Research Update E- Newsletter September – October – November 2016 www.nva.org __________________________ Vulvodynia The Vulvar Pain Assessment Questionnaire inventory. Dargie E, Holden RR, Pukall CF. Pain. 2016 Aug 1. https://www.ncbi.nlm.nih.gov/pubmed/27780177 Millions suffer from chronic vulvar pain (ie, vulvodynia). Vulvodynia represents the intersection of 2 difficult subjects for health care professionals to tackle: sexuality and chronic pain. Those with chronic vulvar pain are often uncomfortable seeking help, and many who do so fail to receive proper diagnoses. The current research developed a multidimensional assessment questionnaire, the Vulvar Pain Assessment Questionnaire (VPAQ) inventory, to assist in the assessment and diagnosis of those with vulvar pain. A large pool of items was created to capture pain characteristics, emotional/cognitive functioning, physical functioning, coping skills, and partner factors. The item pool was subsequently administered online to 288 participants with chronic vulvar pain. Of those, 248 participants also completed previously established questionnaires that were used to evaluate the convergent and discriminant validity of the VPAQ. Exploratory factor analyses of the item pool established 6 primary scales: Pain Severity, Emotional Response, Cognitive Response, and Interference with Life, Sexual Function, and Self-Stimulation/Penetration. A brief screening version accompanies a more detailed version. In addition, 3 supplementary scales address pain quality characteristics, coping skills, and the impact on one's romantic relationship. When relationships among VPAQ scales and previously researched scales were examined, evidence of convergent and discriminant validity was observed. These patterns of findings are consistent with the literature on the multidimensional nature of vulvodynia. The VPAQ can be used for assessment, diagnosis, treatment formulation, and treatment monitoring.
    [Show full text]
  • Table of Contents
    Society for Sex Therapy and Research SSTAR 2008: 33rd Annual Meeting Continuing Medical Education Credit is provided through joint sponsorship with The American College of Obstetricians and Gynecologists (ACOG). Intercontinental Hotel Chicago, Illinois USA March 13-15, 2008 TABLE OF CONTENTS President‘s Welcome ..........................................................................................................1 SSTAR 2009: 34th Annual Meeting – Arlington, Virginia, USA ........................................2 SSTAR 2008 Fall Clinical Meeting – New York, New York USA ....................................2 SSTAR Executive Council and Administrative Staff ..........................................................3 Continuing Education Accreditations & Approvals ............................................................5 Acknowledgements ..............................................................................................................6 Program Schedule ................................................................................................................7 2008 Award Recipients ....................................................................................................14 SSTAR Health Professional Book Award .............................................................14 Sex, Therapy, and Kids Recipient: Sharon Lamb, EdD SSTAR Service Award ..........................................................................................14 Recipient: Bill Maurice, MD SSTAR Student Research Award Abstract ............................................................15
    [Show full text]
  • Co™™I™™Ee Opinion
    The American College of Obstetricians and Gynecologists WOMEN’S HEALTH CARE PHYSICIANS COMMITTEE OPINION Number 673 • September 2016 (Replaces Committee Opinion No. 345, October 2006) Committee on Gynecologic Practice This Committee Opinion was developed by the American College of Obstetricians and Gynecologists’ Committee on Gynecologic Practice and the American Society for Colposcopy and Cervical Pathology (ASCCP) in collaboration with committee member Ngozi Wexler, MD, MPH, and ASCCP members and experts Hope K. Haefner, MD, Herschel W. Lawson, MD, and Colleen K. Stockdale, MD, MS. This document reflects emerging clinical and scientific advances as of the date issued and is subject to change. The information should not be construed as dictating an exclusive course of treatment or procedure to be followed. Persistent Vulvar Pain ABSTRACT: Persistent vulvar pain is a complex disorder that frequently is frustrating to the patient and the clinician. It can be difficult to treat and rapid resolution is unusual, even with appropriate therapy. Vulvar pain can be caused by a specific disorder or it can be idiopathic. Idiopathic vulvar pain is classified as vulvodynia. Although optimal treatment remains unclear, consider an individualized, multidisciplinary approach to address all physical and emotional aspects possibly attributable to vulvodynia. Specialists who may need to be involved include sexual counselors, clinical psychologists, physical therapists, and pain specialists. Patients may perceive this approach to mean the practitioner does not believe their pain is “real”; thus, it is important to begin any treatment approach with a detailed discussion, including an explanation of the diagnosis and determination of realistic treatment goals. Future research should aim at evaluating a multimodal approach in the treatment of vulvodynia, along with more research on the etiologies of vulvodynia.
    [Show full text]
  • The Clinical Role of LASER for Vulvar and Vaginal Treatments in Gynecology and Female Urology: an ICS/ISSVD Best Practice Consensus Document
    Received: 30 November 2018 | Accepted: 3 January 2019 DOI: 10.1002/nau.23931 SOUNDING BOARD The clinical role of LASER for vulvar and vaginal treatments in gynecology and female urology: An ICS/ISSVD best practice consensus document Mario Preti MD1 | Pedro Vieira-Baptista MD2,3 | Giuseppe Alessandro Digesu PhD4 | Carol Emi Bretschneider MD5 | Margot Damaser PhD5,6,7 | Oktay Demirkesen MD8 | Debra S. Heller MD9 | Naside Mangir MD10,11 | Claudia Marchitelli MD12 | Sherif Mourad MD13 | Micheline Moyal-Barracco MD14 | Sol Peremateu MD12 | Visha Tailor MD4 | TufanTarcanMD15 | EliseJ.B.DeMD16 | Colleen K. Stockdale MD, MS17 1 Department of Obstetrics and Gynecology, University of Torino, Torino, Italy 2 Hospital Lusíadas Porto, Porto, Portugal 3 Lower Genital Tract Unit, Centro Hospitalar de São João, Porto, Portugal 4 Department of Urogynaecology, Imperial College Healthcare, London, UK 5 Center for Urogynecology and Pelvic Reconstructive Surgery, Obstetrics, Gynecology and Women's Health Institute, Cleveland Clinic, Cleveland, Ohio 6 Glickman Urological and Kidney Institute and Department of Biomedical Engineering Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 7 Advanced Platform Technology Center, Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio 8 Faculty of Medicine, Department of Urology, Istanbul University Cerrahpaşa, Istanbul, Turkey 9 Department of Pathology and Laboratory Medicine, Rutgers-New Jersey Medical School, Newark, New Jersey 10 Kroto Research Institute, Department of Material Science and Engineering,
    [Show full text]
  • Reproductive Experiences Among Women with Vulvodynia Nora S
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Springer - Publisher Connector Johnson et al. BMC Pregnancy and Childbirth (2015) 15:114 DOI 10.1186/s12884-015-0544-x RESEARCH ARTICLE Open Access “You have to go through it and have your children”: reproductive experiences among women with vulvodynia Nora S. Johnson, Eileen M. Harwood and Ruby H.N. Nguyen* Abstract Background: Vulvodynia is a potentially debilitating chronic pain condition affecting the vulva (external genitalia) in women, with typical age of onset during the early-to mid-reproductive years. Yet, virtually nothing is known about the thoughts, feelings and experience of vulvodynia patients regarding conception, pregnancy and delivery; including the effect that a hallmark symptom, dyspareunia (painful sex), can have on a couple’s physical and emotional ability to conceive. We sought to describe these experiences and beliefs among women with vulvodynia who were pregnant or who recently had delivered a child. Methods: The study used in-depth, qualitative exploratory interview methods to gain a deeper understanding of these experiences for 18 women with vulvar pain who were recruited from an existing, nationally-sampled prospective pregnancy cohort study. Results: Four major themes were reported by our participants. Women described their reaction to pain as volatile at first, and, over time, more self-controlled, regardless of medical treatment; once the volatility became more stable and overall severity lessened, many women began planning for pregnancy. Techniques described by women to cope with pain around pregnancy included pain minimization, planning pregnancy-safe treatment and timing intercourse around ovulation.
    [Show full text]
  • Vulvodynia: a Self-Help Guide
    Vulvodynia: A Self-Help Guide www.nva.org Table of Contents Introduction Introduction ..................................................................................... 1 Welcome to the NVA’s self-help guide for women with vulvodynia. We Section I: Learning the Basics ....................................................... 2 created this guide to answer many of your questions about vulvodynia and Gynecological Anatomy its treatment, and to offer suggestions for improving your quality of life. First Normal and Abnormal Vulvovaginal Symptoms we’d like to highlight a few important points. Vulvar Self-Examination Each woman’s experience with vulvodynia is unique, with symptoms ranging Section II: Understanding Vulvodynia ........................................... 9 from mild to incapacitating. If your pain level is mild, some of the information What is Vulvodynia? in this guide may not apply to you. What Causes Vulvodynia? How is Vulvodynia Diagnosed? Some doctors are still unfamiliar with vulvodynia. Many women spend a long Co-Existing Conditions time wondering what is wrong with them and see several doctors before How is Vulvodynia Treated? they are told they have vulvodynia. An accurate diagnosis is half the battle, Self-Help Strategies for Vulvar Pain so now you can focus your efforts on finding helpful treatments and feeling better. Section III: Understanding Chronic Pain ..................................... 17 How We Feel Pain When you start a new treatment, try to be patient and hopeful. There are When Pain Becomes Chronic many treatment options for vulvodynia and no single treatment works equally Coping with Chronic Pain well for all women. Sometimes progress is slow and you may only notice improvement on a monthly, rather than daily, basis. Section IV: Quality of Life Issues ................................................. 20 Overcoming Challenges in Your Intimate Relationship It is important to participate in treatment decisions and discuss your progress Keeping Sexual Intimacy Alive (or lack of it) with your doctor or other health care provider.
    [Show full text]
  • SJH Procedures
    SJH Procedures - Gynecology and Gynecology Oncology Services New Name Old Name CPT Code Service ABLATION, LESION, CERVIX AND VULVA, USING CO2 LASER LASER VAPORIZATION CERVIX/VULVA W CO2 LASER 56501 Destruction of lesion(s), vulva; simple (eg, laser surgery, Gynecology electrosurgery, cryosurgery, chemosurgery) 56515 Destruction of lesion(s), vulva; extensive (eg, laser surgery, Gynecology electrosurgery, cryosurgery, chemosurgery) 57513 Cautery of cervix; laser ablation Gynecology BIOPSY OR EXCISION, LESION, FACE AND NECK EXCISION/BIOPSY (MASS/LESION/LIPOMA/CYST) FACE/NECK General, Gynecology, Plastics, ENT, Maxillofacial BIOPSY OR EXCISION, LESION, FACE AND NECK, 2 OR MORE EXCISE/BIOPSY (MASS/LESION/LIPOMA/CYST) MULTIPLE FACE/NECK 11102 Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); General, Gynecology, single lesion Aesthetics, Urology, Maxillofacial, ENT, Thoracic, Vascular, Cardiovascular, Plastics, Orthopedics 11103 Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); General, Gynecology, each separate/additional lesion (list separately in addition to Aesthetics, Urology, code for primary procedure) Maxillofacial, ENT, Thoracic, Vascular, Cardiovascular, Plastics, Orthopedics 11104 Punch biopsy of skin (including simple closure, when General, Gynecology, performed); single lesion Aesthetics, Urology, Maxillofacial, ENT, Thoracic, Vascular, Cardiovascular, Plastics, Orthopedics 11105 Punch biopsy of skin (including simple closure, when General, Gynecology, performed); each separate/additional lesion
    [Show full text]
  • Female Sexual Dysfunction Alessandra Graziottin
    266 PELVIC FLOOR DYSFUNCTION AND EVIDENCE-BASED PHYSICAL THERAPY Female sexual dysfunction Alessandra Graziottin ASSESSMENT Last, but not least, new insights into the role of the hyperactivity of the pelvic fl oor in adolescence and, Women’s sexuality has only recently emerged as a possibly, infanthood, as predictors of vulnerability to central concern after years of neglect in the medical further sexual pain disorders (vaginismus and dyspa- world. The current challenge is to blend together the reunia) and to vulvar vestibulitis/vulvodynia open a biological, psychosexual and context-related compo- new preventive window for female sexual dysfunctions nents of women’s sexual response in a comprehensive (FSD) (Chiozza & Graziottin 2004, Graziottin 2005a, and meaningful scenario (Basson et al 2000, 2004). In Harlow et al 2001). Appropriate management of early this perspective, the role of pelvic fl oor function and hyperactivity of the pelvic fl oor could hopefully prevent dysfunction is of the highest importance (Alvarez & the urogenital and sexual comorbidities that affect so Rockwell 2002, Bourcier et al 2004, Graziottin 2001a, many young lives. 2005a). In this book, dedicated to physical therapy for the Levator ani’s tone, strength and performance is a pelvic fl oor, FSD is reviewed paying special attention to major contributor to vaginal receptivity, vaginal respon- the genital components of women’s sexual response in siveness, coital competence and pleasure (for both part- physiological and pathological conditions. However, ners), and for the orgasmic muscular response. Indirectly, the role of the biological and medical factors should pelvic fl oor disorders (PFD) may impair genital arousal always be considered in the appropriate psychosexual and, through a negative feedback, may affect the poten- and sociocultural context.
    [Show full text]
  • Dk3608 C000 1..18
    3608_title 7/6/06 9:52 AM Page 1 Anatomy,The Physiology, Vulva and Pathology Edited by MirandaThe Procter & Gamble A. CompanyFarage Cincinnati, Ohio, U.S.A. HowardUniversity of California I. Maibach School of Medicine San Francisco, California, U.S.A. New York London Informa Healthcare USA, Inc. 270 Madison Avenue New York, NY 10016 © 2006 by Informa Healthcare USA, Inc. Informa Healthcare is an Informa business No claim to original U.S. Government works Printed in the United States of America on acid-free paper 10 9 8 7 6 5 4 3 2 1 International Standard Book Number-10: 0-8493-3608-2 (Hardcover) International Standard Book Number-13: 978-0-8493-3608-9 (Hardcover) This book contains information obtained from authentic and highly regarded sources. Reprinted material is quoted with permission, and sources are indicated. A wide variety of references are listed. Reasonable efforts have been made to publish reliable data and information, but the author and the publisher cannot assume responsibility for the validity of all materials or for the conse- quences of their use. No part of this book may be reprinted, reproduced, transmitted, or utilized in any form by any electronic, mechanical, or other means, now known or hereafter invented, including photocopy- ing, microfilming, and recording, or in any information storage or retrieval system, without writ- ten permission from the publishers. For permission to photocopy or use material electronically from this work, please access www. copyright.com (http://www.copyright.com/) or contact the Copyright Clearance Center, Inc. (CCC) 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400.
    [Show full text]
  • Current Uses of Surgery in the Treatment of Genital Pain Michelle King, Rachel Rubin & Andrew T. Goldstein
    Current Uses of Surgery in the Treatment of Genital Pain Michelle King, Rachel Rubin & Andrew T. Goldstein Current Sexual Health Reports ISSN 1548-3584 Curr Sex Health Rep DOI 10.1007/s11930-014-0032-8 1 23 Your article is protected by copyright and all rights are held exclusively by Springer Science+Business Media, LLC. This e-offprint is for personal use only and shall not be self- archived in electronic repositories. If you wish to self-archive your article, please use the accepted manuscript version for posting on your own website. You may further deposit the accepted manuscript version in any repository, provided it is only made publicly available 12 months after official publication or later and provided acknowledgement is given to the original source of publication and a link is inserted to the published article on Springer's website. The link must be accompanied by the following text: "The final publication is available at link.springer.com”. 1 23 Author's personal copy Curr Sex Health Rep DOI 10.1007/s11930-014-0032-8 FEMALE SEXUAL DYSFUNCTION AND DISORDERS (A GIRALDI AND L BROTTO, SECTION EDITORS) Current Uses of Surgery in the Treatment of Genital Pain Michelle King & Rachel Rubin & Andrew T. Goldstein # Springer Science+Business Media, LLC 2014 Abstract Genital pain frequently causes sexual dysfunction during sexual intercourse, vary greatly. However, it has and psychological distress that can impact every aspect of a been suggested that as many as 17–19 % of women woman’s life. When conservative medical treatments do not have a lifetime prevalence of dyspareunia [1].
    [Show full text]
  • Female Genital Cosmetic Surgery: a Review of Techniques and Outcomes
    Int Urogynecol J (2013) 24:1997–2009 DOI 10.1007/s00192-013-2117-8 REVIEW ARTICLE Female genital cosmetic surgery: a review of techniques and outcomes Cheryl B. Iglesia & Ladin Yurteri-Kaplan & Red Alinsod Received: 15 April 2013 /Accepted: 18 April 2013 /Published online: 22 May 2013 # The International Urogynecological Association 2013 Abstract The aesthetic and functional procedures that com- Keyword Female genital cosmetic surgery . Cosmetic prise female genital cosmetic surgery (FGCS) include tradi- gynecology . Vaginal rejuvenation . Labiaplasty . tional vaginal prolapse procedures as well as cosmetic Vaginoplasty vulvar and labial procedures. The line between cosmetic and medically indicated surgical procedures is blurred, and today many operations are performed for both purposes. The Introduction contributions of gynecologists and reconstructive pelvic surgeons are crucial in this debate. Aesthetic vaginal sur- Consumer marketing and media hype have spawned the con- geons may unintentionally blur legitimate female pelvic siderable controversy over female genital cosmetic surgery floor disorders with other aesthetic conditions. In the ab- (FGCS). FGCS articles first appeared in North American sence of quality outcome data, the value of FGCS in im- journals in 1978, and the first technical article appeared in proving sexual function remains uncertain. Women seeking 1984 [1, 2]. This review describes the techniques and outcome FGCS need to be educated about the range and variation of data of labiaplasty, vaginoplasty, and other cosmetic gyneco- labia widths and genital appearance, and should be evaluat- logical procedures. ed for true pelvic support disorders such as pelvic organ prolapse and stress urinary incontinence. Women seeking FGCS should also be screened for psychological conditions Female genital perceptions and should act autonomously without coercion from part- ners or surgeons with proprietary conflicts of interest.
    [Show full text]
  • Research Day Brochure 2021
    Obstetrics, Gynecology & Women’s Health Institute 6TH ANNUAL Research Day May 12, 2021 via Webex 6TH ANNUAL Obstetrics, Gynecology & Women’s Health Institute RESEARCH DAY May 12, 2021 2 Discovery Translational Clinical Research Research Research Key Note Address & Lecture Paula Amato, MD, MCR Professor Department of Obstetrics and Gynecology Division of Reproductive Endocrinology & Infertility Oregon Health & Science University Judges (Oral Presentations) Mariam AlHilli, MD Paula Amato, MD Mariam Cremer, MD, MPH Jeffrey Goldberg, MD Rosanne Kho, MD Giancarlo Mari, MD Shannon Wallace, MD Judges (Poster Presentations) Cara King, DO Justin Lappen, MD Amy Park, MD Stephanie Ricci, MD Elliott Richards, MD 3 Agenda 7:45 am Presenter & Judges Registration 8:15–8:20 am Welcome Chad Michener, MD Interim Institute Chair, Ob/Gyn & Women’s Health Institute 8:20–8:25 am Introduction & Welcome Ruth Farrell, MD, MA Vice Chair, Research, Ob/Gyn & Women’s Health Institute 8:25–9:10 am Key Note Address Germline Gene Therapy: Promise & Peril Paula Amato, MD Professor, Department of Obstetrics and Gynecology Division of Reproductive Endocrinology and Infertility Oregon Health & Science University Center for Health & Healing 9:10–9:15 am Q&A 9:15–10:30 am Graduating Fellow Oral Presentations 9:15 am Development and validation of the Value of Uterus (VALUS) instrument for women undergoing pelvic organ prolapse surgery Olivia Chang, MD, MPH Fellow, Female Pelvic Medicine & Reconstructive Surgery 9:25 am Q&A 9:30 am Antibiotic treatment worsens outcomes following
    [Show full text]